Management of Hypertension in Pregnancy

Classification

Key diagnostic update: Proteinuria is no longer required to diagnose preeclampsia if other organ dysfunction criteria (AKI, transaminitis, thrombocytopenia, CNS or hepatic abnormalities, uteroplacental dysfunction) are present.

Blood Pressure Thresholds for Treatment

Non-Severe Hypertension (BP 140–159/90–109 mmHg)

• The CHIPS trial demonstrated that tight BP control (target DBP 85 mmHg) versus less-tight control (target DBP 100 mmHg) did not impair fetal outcomes but significantly reduced severe hypertension, thrombocytopenia, and transaminitis in the mother.
• The 2025 AHA/ACC Hypertension Guideline now recommends treating chronic hypertension in pregnancy to a goal of < 140/90 mmHg — a shift from prior guidance that deferred treatment for BP below 160/105.
• Previous guidance (ACOG 2013) advised against treatment if BP <160/105 in the absence of end-organ damage, citing concern for reduced uteroplacental perfusion; this has been updated based on the CHIPS and CHAP trial evidence.

Severe Hypertension (SBP ≥ 160 or DBP ≥ 105–110 mmHg)

• Treatment is mandatory to prevent stroke and maternal cardiovascular complications.
• Per 2025 AHA/ACC: antihypertensive therapy must be initiated within 30–60 minutes of confirmed severe readings (confirmed on repeat measurement within 15 min).
• Target: reduce BP promptly but avoid precipitous drops that could compromise uteroplacental flow.

Antihypertensive Drug Selection

First-Line Oral Agents

Acute/IV Management (Severe Hypertension)

Second-Line Oral Agents

• Metoprolol (long-acting formulation available; less data than labetalol)
• Verapamil, diltiazem (limited data; no evidence of fetal harm)

Agents to Avoid / Contraindicated

Preeclampsia: Prevention

Low-Dose Aspirin

• Recommended beginning at 10–12 weeks for patients with chronic hypertension or at elevated risk of preeclampsia.
• Mechanism: inhibits thromboxane-mediated platelet aggregation and vasoconstriction while sparing prostacyclin production.
• USPSTF recommends 81 mg/day for all high-risk women starting 12–28 weeks (optimally before 16 weeks).

Calcium Supplementation

• Recommended in populations with low dietary calcium intake (Cochrane evidence supports reduction in severe preeclampsia and maternal mortality).

Preeclampsia: Definitive Treatment — Delivery

• Delivery is the only cure for preeclampsia.
• At ≥37 weeks: delivery is indicated.
• Severe preeclampsia with fetal maturity: delivery after maternal stabilization.
• Severe preeclampsia at <34 weeks in a stable patient: expectant management may allow fetal maturation, with close in-hospital monitoring.

Seizure Prophylaxis: Magnesium Sulfate

• Gold standard for eclampsia prevention and treatment in women with severe preeclampsia.
• Given for CNS manifestations: headache, visual disturbance, altered mental status.
• Loading dose: 4–6 g IV over 15–20 min; maintenance: 1–2 g/hr IV.
• Also recommended postpartum: ~20% of eclampsia cases occur >48 hours after delivery.
• Monitor for toxicity: respiratory depression (Mg >7–8 mEq/L), loss of patellar reflexes. Antidote: calcium gluconate.

Chronic Hypertension in Pregnancy: Pre-conception Approach

• Evaluate for secondary causes before or early in pregnancy: renal artery stenosis, primary hyperaldosteronism, pheochromocytoma, obstructive sleep apnea (40% of pregnant women with HTN had OSA in one polysomnography study).
• Switch to pregnancy-safe agents before conception.
• Counsel on risks: preeclampsia, preterm birth, IUGR.
• Screen for superimposed preeclampsia throughout pregnancy.

Postpartum Management

• Most antihypertensives are compatible with breastfeeding; nifedipine and labetalol are preferred.
• BP often spikes in the first 3–5 days postpartum — monitor closely.
• Women with preeclampsia have long-term cardiovascular risk: chronic hypertension, CKD, CVD later in life — flag for ongoing surveillance.
• A 2024 systematic review (PMID 39806714) found nifedipine and labetalol are the most studied oral agents for postpartum hypertension management.

2025 AHA/ACC Key Updates (Pregnancy-Specific)

1. Treat chronic HTN to <140/90 mmHg (not the prior permissive 160/105 threshold for mild HTN)
2. Severe HTN: medications must be given within 30–60 minutes of confirmed BP ≥160/110
3. Expanded contraindicated list: now explicitly includes atenolol, ACE inhibitors, ARBs, direct renin inhibitors, nitroprusside, and MRAs
4. Low-dose aspirin starting 10–12 weeks for preeclampsia prevention

Summary: Quick-Reference Algorithm

BP ≥ 140/90 in pregnancy?
│
├─ Before 20 weeks → Likely chronic HTN (rule out white-coat)
│   → Switch to safe agent (methyldopa / labetalol / nifedipine)
│   → Screen for secondary HTN
│   → Aspirin 81 mg from 10–12 weeks
│
├─ After 20 weeks, no features of preeclampsia → Gestational HTN
│   → Monitor weekly; treat BP to <140/90
│
├─ After 20 weeks + organ dysfunction → Preeclampsia
│   → Admit; antihypertensives + MgSO₄ prophylaxis
│   → Plan delivery based on gestation and severity
│
└─ BP ≥ 160/110 (severe) at any time
    → IV labetalol or oral nifedipine
    → Treat within 30–60 minutes
    → MgSO₄ if any CNS features